Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseStem Cell TransplantationTransplantation ConditioningHematologic NeoplasmsHematopoietic Stem CellsTransplantation, AutologousPeripheral Blood Stem Cell TransplantationTransplantation ChimeraGraft vs Leukemia EffectTissue DonorsMyeloablative AgonistsTreatment OutcomeBone Marrow TransplantationStem CellsBusulfanGraft vs Tumor EffectRecurrenceVidarabineGraft SurvivalHistocompatibility TestingRetrospective StudiesLeukemiaHistocompatibilityWhole-Body IrradiationRemission InductionChimerismLymphocyte TransfusionLeukemia, Myeloid, AcuteCord Blood Stem Cell TransplantationSurvival RateSiblingsImmunosuppressive AgentsMyelodysplastic SyndromesHematologic DiseasesCytomegalovirus InfectionsSurvival AnalysisDisease-Free SurvivalPrecursor Cell Lymphoblastic Leukemia-LymphomaCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHepatic Veno-Occlusive DiseaseHLA AntigensMultiple MyelomaAllograftsMinor Histocompatibility AntigensTime FactorsLymphocyte DepletionSalvage TherapyNeoplasm, ResidualAcute DiseaseAntilymphocyte SerumT-LymphocytesLiver TransplantationTransplantation ImmunologyAnemia, AplasticHematopoietic Stem Cell MobilizationCyclophosphamideFollow-Up StudiesCytomegalovirusTransplantation, IsogeneicAntigens, CD34Opportunistic InfectionsLymphoproliferative DisordersAntineoplastic Combined Chemotherapy ProtocolsMesenchymal Stem Cell TransplantationPrognosisFlow CytometryMelphalanVirus ActivationImmunocompromised HostPrimary MyelofibrosisHematopoiesisImmunosuppressionCell TransplantationLeukemia, MyeloidBone Marrow CellsRisk FactorsEmbryonic Stem CellsSevere Combined ImmunodeficiencyLeukemic InfiltrationCystitisKidney TransplantationCell DifferentiationFatal OutcomeCytarabineMice, Inbred C57BLGanciclovirMycosesAntibodies, NeoplasmAdult Stem CellsAntineoplastic AgentsGraft RejectionCyclosporinePyrimidinesProspective StudiesBronchiolitis ObliteransStem Cell NicheGranulocyte Colony-Stimulating Factor